Acadia Healthcare Company's fair value has been revised downward, primarily driven by a notable decline in its projected future P/E and an increased discount rate, resulting in a lower consensus price target from $41.86 to $38.21.
What's in the News
- Acadia Healthcare completed a buyback of 1,706,807 shares (1.84% of shares outstanding) for $50.02 million as of June 30, 2025.
- The company updated its 2025 revenue guidance to $3.3 billion to $3.35 billion, narrowing the previous range of $3.3 billion to $3.4 billion.
- Chief Financial Officer Heather Dixon will step down effective August 15, 2025; Timothy Sides, SVP of Operations Finance, will serve as interim CFO while a nationwide search is conducted for a permanent replacement.
Valuation Changes
Summary of Valuation Changes for Acadia Healthcare Company
- The Consensus Analyst Price Target has fallen from $41.86 to $38.21.
- The Future P/E for Acadia Healthcare Company has significantly fallen from 14.71x to 12.12x.
- The Discount Rate for Acadia Healthcare Company has risen from 7.05% to 7.53%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.